WallStreetZenWallStreetZen
Analyst Ranking
Bottom 8%
#3811 out of 4129 analysts
Average Return
-8.03%
Win Rate
41%17 out of 41
Risk vs Reward
Poor
Good

Evan Seigerman's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Eli Lilly & CoLLY
+38.73%$260.70$361.67
2021-11-19 -
2022-11-18
Buy
Vertex Pharmaceuticals IncVRTX
+36.39%$228.61$311.81
2022-01-20 -
2022-12-06
Buy
Bristol Myers Squibb CoBMY
+33.93%$57.83$77.45
2021-11-19 -
2022-11-18
Buy
Regeneron Pharmaceuticals IncREGN
+28.81%$468.03$602.89
2021-02-23 -
2022-02-22
Buy
Regeneron Pharmaceuticals IncREGN
+27.46%$376.42$479.77
2019-12-13 -
2020-12-11
Buy

Evan Seigerman's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Replimune Group IncREPL
1Buy$40.00+111.75%Maintains
2 months ago
Biogen IncBIIB
7Buy$360.00+23.51%Upgrades
2 months ago
Bristol Myers Squibb CoBMY
4Buy$94.00+17.62%Maintains
3 months ago
Regeneron Pharmaceuticals IncREGN
9Buy$788.00+5.42%Maintains
4 months ago
Nuvation Bio IncNUVB
2Hold$2.50+25.63%Downgrades
4 months ago
Gilead Sciences IncGILD
7Hold$63.00-28.38%Maintains
7 months ago
Eli Lilly & CoLLY
2Buy$358.00-2.86%Maintains
7 months ago
Candel Therapeutics IncCADL
2Buy$12.00+618.56%Maintains
8 months ago
Vertex Pharmaceuticals IncVRTX
5Buy$274.00-12.13%Upgrades
a year ago
Mirati Therapeutics IncMRTX
3Buy$187.00N/AInitiates Coverage On
a year ago
Pfizer IncPFE
1Buy$60.00N/AInitiates Coverage On
a year ago
Incyte CorpINCY
2Hold$75.00N/AInitiates Coverage On
a year ago
Amgen IncAMGN
4Hold$228.00N/AInitiates Coverage On
a year ago
Neurocrine Biosciences IncNBIX
3Sell$76.00N/AInitiates Coverage On
a year ago
Ikena Oncology IncIKNA
1Buy$30.00N/AInitiates Coverage On
2 years ago
Satsuma Pharmaceuticals IncSTSA
2Hold$6.50N/AUpgrades
2 years ago
Galera Therapeutics IncGRTX
2Buy$15.00N/AUpgrades
2 years ago
Aimmune Therapeutics IncAIMT
3Hold$34.50N/AMaintains
2 years ago
Acelrx Pharmaceuticals IncACRX
1Sell$0.69N/ADowngrades
2 years ago
Macrogenics IncMGNX
1Buy$13.00N/AMaintains
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.